文献速递免疫规划卫生政策与健康促进

印度伤寒疫苗接种的成本效果分析

Cost effectiveness of typhoid vaccination in India.
PubMed 文献 · Vaccine · 2021-06-10

该研究采用决策分析模型,从社会视角比较印度城乡新生儿队列(10万儿童)接种伤寒结合疫苗(TCV)与不接种的长期成本与效果(3%贴现率),模拟疫苗保护期5年、10年和15年三种情景。结果显示,城市地区引入TCV可节约成本,而农村地区因伤寒发病率低,TCV接种不具有成本效果。

要点

  • 城市地区接种TCV可预防17%至36%的伤寒病例和死亡。
  • 城市地区含间接成本时,三种接种情景均节约成本。
  • 农村地区因发病率低,接种TCV不具有成本效果。

核心结论

  • 从社会视角看,印度城市地区引入TCV是节约成本的策略。
  • 由于伤寒发病率低,印度农村地区引入TCV不具有成本效果。

研究设计与样本

  • 决策分析模型,采用社会视角,比较10万新生儿队列接种或不接种TCV的长期成本与结果(3%贴现率)。
  • 模拟三种疫苗接种情景,假设TCV保护效力持续5年、10年和15年。
  • 伤寒感染发病率采用「国家肠道热监测系统」(NSSEFI)的估计值。

主要发现

  • 城市地区引入TCV可预防17%至36%的伤寒病例和死亡。
  • 城市地区不含间接成本时,每获得一个QALY的增量成本:情景1为₹151,346(54,730-307,975),情景2为₹61,710(-5250至163,283),情景3为₹45,188(-17,069至141,093)。
  • 城市地区含间接成本时,三种情景均节约成本。
  • 农村地区TCV预计减少19%至36%的伤寒病例和死亡,含间接成本的ICER范围为₹2340(1316-4370)至₹3574(2057-6691)千。

临床怎么用

  • 在城市地区可优先考虑引入TCV以降低伤寒负担并节约社会成本。
  • 农村地区引入TCV前需结合当地伤寒发病率评估成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: World Health Organization has prequalified the use of typhoid conjugate vaccine (TCV) in children over six months of age in typhoid endemic countries. We assessed the cost-effectiveness of introducing TCV separately for urban and rural areas of India. METHODS: A decision analytic model was developed, using a societal perspective, to compare long-term costs and outcomes (3% discount rate) in a new-born cohort of 100,000 children immunized with or without TCV. Three vaccination scenarios were modelled, assuming the protective efficacy of TCV to last for 5, 10 and 15 years following immunization. Incidence of typhoid infection estimated under 'National Surveillance System for Enteric Fever' (NSSEFI)' was used. The prices of vaccine and cost of service delivery were included for vaccination arm. Both health system cost and out-of-pocket expenditures for treatment of typhoid illness and its complications was included. RESULTS: TCV introduction in urban areas would result in prevention of 17% to 36% typhoid cases and deaths. With exclusion of indirect costs, the incremental cost per QALY gained was ₹ 151,346 (54,730-307,975), ₹ 61,710 (-5250 to 163,283) and ₹ 45,188 (-17,069 to 141,093) for scenario 1, 2 and 3 respectively. While, with inclusion of indirect costs, all 3 scenarios were cost saving. Further, in rural areas, TCV is estimated to reduce the typhoid cases and deaths by 19% to 36%, with ICER (incremental cost per QALY gained) ranging from ₹ 2340 (1316-4370) to ₹ 3574 (2057 - 6691) thousand (inclusive of indirect costs) among the 3 vaccination scenarios. CONCLUSION: From a societal perspective, introduction of TCV is a cost saving strategy in urban India. Further, due to low incidence of typhoid infection, introduction of TCV is not cost-effective in rural settings of India.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chauhan AS, Kapoor I, Rana SK, et al. Cost effectiveness of typhoid vaccination in India. Vaccine. 2021. PMID: 34120765. doi:10.1016/j.vaccine.2021.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。